Evidence map›Paper›PMID 12610744›Full record

Trial reportEuropean journal of clinical pharmacology2003

Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo.

Päivi K Myllynen, Päivi K Pienimäki, Kirsi H Vähäkangas

Abstract readClinical TrialComparative StudyControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Lamotrigine dosing for pregnant patients with bipolar disorder.The American journal of psychiatry · 2013
    Article
  7. Drug transporters in the human blood-placental barrier.British journal of pharmacology · 2009
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Päivi K MyllynenDepartment of Pharmacology and Toxicology, University of Oulu, PO Box 5000, FIN-90014, Oulu, Finland. paivi.k.myllynen@oulu.fi
Päivi K Pienimäki
Kirsi H Vähäkangas
University of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe studied transplacental passage of lamotrigine (3,5-diamino-6-[2,3-dichlorophenyl]-1,2,4-triazine; LTG) using an ex vivo human placental perfusion method and in in vivo samples.

methodsTerm placentas from healthy mothers without medications were perfused in a recirculating dual perfusion system. LTG (2.5 microg/ml, n=4; 10 microg/ml, n=4) and reference compound antipyrine (100 microg/ml) were added into the maternal circulation. The disappearance of drugs from the maternal circulation and appearance into the foetal circulation was followed every 15 min up to 2 h. Drug concentrations were analysed using high-performance liquid chromatography. In addition to human placental perfusions, we analysed LTG concentrations in maternal vein and cord blood samples after delivery from two epileptic mothers receiving LTG therapy during pregnancy.

resultsLTG was detectable in the foetal circulation at 15 min in all of the perfusions, indicating rapid transfer. Maternal and foetal concentrations reached equilibrium at 60 min with both concentrations used. The feto-maternal ratio was 1.26+/-0.20 with 10 microg/ml LTG and 0.83+/-0.41 with 2.5 microg/ml LTG at the end of the perfusion. The transfer of LTG from the maternal to the foetal compartment at 120 min was 28.9+/-10.7% with 2.5 microg/ml LTG and 37.8+/-3.2% with 10 microg/ml LTG (p>0.05). In the serum samples from epileptic mothers, the cord blood maternal concentration ratio was 1.02 in one pair and 1.55 in the other.

conclusionsLTG crossed the placenta easily and rapidly, indicating that the maternal treatment leads to a considerable foetal exposure.

Indexed as

Maternal-Fetal ExchangeAnticonvulsantsAntipyrineChromatography, High Pressure LiquidDose-Response Relationship, DrugFemaleFetal BloodHumansHydrogen-Ion ConcentrationIn Vitro TechniquesLamotriginePlacentaPregnancyTime FactorsTriazinesAnticonvulsantsAntipyrineLamotrigineTriazines

Identifiers

PMID12610744
OpenAlexW1583622582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.